BRPI0212999B8 - novas composições imunogênicas para a prevenção e tratamento de doença meningocócica - Google Patents

novas composições imunogênicas para a prevenção e tratamento de doença meningocócica

Info

Publication number
BRPI0212999B8
BRPI0212999B8 BRPI0212999A BRPI0212999A BRPI0212999B8 BR PI0212999 B8 BRPI0212999 B8 BR PI0212999B8 BR PI0212999 A BRPI0212999 A BR PI0212999A BR PI0212999 A BRPI0212999 A BR PI0212999A BR PI0212999 B8 BRPI0212999 B8 BR PI0212999B8
Authority
BR
Brazil
Prior art keywords
immunogenic compositions
prevention
treatment
meningococcal disease
immunogenic
Prior art date
Application number
BRPI0212999A
Other languages
English (en)
Portuguese (pt)
Inventor
J Metcalf Benjamin
W Zlotnick Gary
Farley John
D Fletcher Leah
A Bernfield Liesel
J Zagursky Robert
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0212999(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0212999A publication Critical patent/BR0212999A/pt
Publication of BRPI0212999B1 publication Critical patent/BRPI0212999B1/pt
Publication of BRPI0212999B8 publication Critical patent/BRPI0212999B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0212999A 2001-10-11 2002-10-11 novas composições imunogênicas para a prevenção e tratamento de doença meningocócica BRPI0212999B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US60/328,101 2001-10-11
US40693402P 2002-08-30 2002-08-30
US60/406,934 2002-08-30
PCT/US2002/032369 WO2003063766A2 (en) 2001-10-11 2002-10-11 Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Publications (3)

Publication Number Publication Date
BR0212999A BR0212999A (pt) 2006-05-23
BRPI0212999B1 BRPI0212999B1 (pt) 2020-04-28
BRPI0212999B8 true BRPI0212999B8 (pt) 2021-07-27

Family

ID=27668840

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212999A BRPI0212999B8 (pt) 2001-10-11 2002-10-11 novas composições imunogênicas para a prevenção e tratamento de doença meningocócica

Country Status (18)

Country Link
US (13) US8101194B2 (enExample)
EP (14) EP2348035B1 (enExample)
JP (6) JP2005515771A (enExample)
KR (4) KR20100121699A (enExample)
CN (4) CN1578785B (enExample)
AU (3) AU2009213040C1 (enExample)
BE (3) BE2017C057I2 (enExample)
BR (1) BRPI0212999B8 (enExample)
CA (5) CA2849427C (enExample)
DK (10) DK2351767T3 (enExample)
ES (14) ES2615206T3 (enExample)
FR (4) FR15C0056I2 (enExample)
IL (5) IL161052A0 (enExample)
LU (4) LU92786I2 (enExample)
MX (3) MX339524B (enExample)
NL (4) NL300755I2 (enExample)
PT (10) PT2371836T (enExample)
WO (1) WO2003063766A2 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261350A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
EP2270172B1 (en) 1999-05-19 2016-01-13 GlaxoSmithKline Biologicals SA Combination neisserial compositions
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
EP1261723B1 (en) 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ562998A (en) 2002-10-11 2008-05-30 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CN1867354A (zh) * 2003-04-16 2006-11-22 惠氏控股有限公司 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
SI1868645T1 (sl) 2005-04-08 2012-04-30 Wyeth Llc Večvalentni pnevmokokni sestavek konjugata polisaharid-protein
UA95237C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
ES2788001T3 (es) 2006-07-27 2020-10-20 Wyeth Llc Procedimiento de fermentación de alimentación discontinua de alta densidad celular para producir proteínas recombinantes
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
RU2555757C2 (ru) * 2009-03-24 2015-07-10 Новартис Аг Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
BR112012004276A2 (pt) 2009-08-27 2017-10-24 Novartis Ag adjuvante compreendendo alumínio, oligonucleotídeo e policátion
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP4036104B1 (en) * 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
SI2575870T1 (sl) 2010-06-04 2017-01-31 Wyeth Llc Formulacije cepiva
EP2585106A1 (en) * 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
RU2013144207A (ru) 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
WO2012153302A1 (en) 2011-05-12 2012-11-15 Novartis Ag Antipyretics to enhance tolerability of vesicle-based vaccines
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
AU2013214105A1 (en) 2012-02-02 2014-07-24 Novartis Ag Promoters for increased protein expression in meningococcus
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2960030C (en) * 2012-03-09 2020-02-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112014031386A2 (pt) * 2012-06-14 2017-08-01 Pasteur Institut vacinas para meningococos do sorogrupo x
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX2016001412A (es) 2013-08-02 2016-10-28 Children ' S Hospital & Res Center Oakland Proteinas de union al factor h (fhbp) de origen no natural y métodos de uso de estas.
AU2014316722B2 (en) * 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP3172224B1 (en) * 2014-07-23 2022-06-29 Children's Hospital & Research Center at Oakland Factor h binding protein variants and methods of use thereof
US11031102B2 (en) 2014-11-17 2021-06-08 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CN106434720A (zh) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 提高脑膜炎奈瑟菌fHBP蛋白表达的方法
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
DK3506935T3 (en) 2016-09-02 2024-04-02 Sanofi Pasteur Inc Neisseria meningitidis-vaccine
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法
WO2019065555A1 (ja) 2017-09-28 2019-04-04 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
WO2019065554A1 (ja) * 2017-09-28 2019-04-04 富士フイルム株式会社 撮像装置、情報取得方法及び情報取得プログラム
TWI687696B (zh) * 2019-06-26 2020-03-11 國立中興大學 回饋型隱藏式馬可夫模型辨識器的建立方法與基於此辨識器的辨識系統的建立方法
AU2020355401B2 (en) 2019-09-27 2025-03-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN114681601B (zh) * 2020-12-31 2025-08-19 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
JP2024507828A (ja) * 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド Ｂ群髄膜炎菌組換えワクチン
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
CN118613207A (zh) 2022-01-24 2024-09-06 皇家飞利浦有限公司 使用血管内数据与管腔外图像之间的共配准的脉搏波速度确定以及相关联的系统、设备和方法
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用
CN120241991B (zh) * 2025-06-05 2025-12-23 北京绿竹生物技术股份有限公司 一种新型的b群流脑外膜蛋白双功能载体

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (de) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Schaltungsanordnung zur Steuerung des zur Zwischenspeicherung des Zeitwertes eines Signales verwendeten Kondensators eines Demodulators einer Zeitmultiplexanlage
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (it) * 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
RU2023448C1 (ru) 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
JPH01144977A (ja) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol 新規組換えプラスミドｐＴＰＧＩＦ２
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0432216A1 (en) 1988-09-01 1991-06-19 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
KR100188323B1 (ko) 1989-03-09 1999-06-01 이곤 이이 버어그 비타입성 헤모필루스 인플렌자에 대한 백신
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
JPH0453645U (enExample) * 1990-09-12 1992-05-07
KR100372934B1 (ko) 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
EP0625052A4 (en) 1991-10-21 1995-07-19 Medimmune Inc SECRETION SIGNAL OF LIPOPROTEIN-ENCODING DNA CONTAINING BACTERIAL EXPRESSION VECTOR.
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015115A1 (en) * 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
DK0616034T3 (da) * 1993-03-05 2005-02-21 Wyeth Corp Plasmid til fremstilling af CRM-protein og diphtheria toxin
CA2158148A1 (en) 1993-03-19 1994-09-29 Stephen Charles Inglis Defective mutant non-retroviral virus (e.g. hsv) as vaccine
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FI951138A7 (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FI98045C (fi) 1994-02-21 1997-04-10 Arto Remes Laite inkontinenssihoitoa varten
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995028494A1 (en) 1994-04-15 1995-10-26 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE173634T1 (de) * 1994-04-20 1998-12-15 Us Army Impfstoff gegen gram-negative bakterielle infektionen
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
WO1996039036A1 (en) 1995-06-05 1996-12-12 The University Of Alabama At Birmingham Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
PT832093E (pt) * 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expressão de lipoproteínas
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
WO1998017805A2 (en) 1996-10-24 1998-04-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office Invasion associated genes from neisseria meningitidis serogroup b
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
HUP0004589A3 (en) 1997-06-30 2003-08-28 Centre Nat Rech Scient Improved method for transferring nucleic acid into the striped muscle and combination therefor
KR20010020570A (ko) 1997-06-30 2001-03-15 자끄 사비나 다세포 진핵 생물 세포중으로 개선된 핵산 전달방법 및이를 위한 콤비네이션
IL133709A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
NZ502437A (en) * 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
JPH1144977A (ja) 1997-07-25 1999-02-16 Copyer Co Ltd 画像形成装置
US6030619A (en) 1997-08-27 2000-02-29 Chiron Corporation Molecular mimetics of meningococcal B epitopes
EP1012192B1 (en) * 1997-08-29 2002-10-23 The Dow Chemical Company Homogeneous filled polymer composite
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP4399112B2 (ja) 1998-01-14 2010-01-13 カイロン ソチエタ ア レスポンサビリタ リミタータ ＮｅｉｓｓｅｒｉａＭｅｎｉｎｇｉｔｉｄｉｓ抗原
NZ525674A (en) * 1998-02-03 2005-01-28 Ct Disease Contr & Prevention Recombinant lipidated PsaA protein, methods of preparation and use
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
EP2261350A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP2796148A3 (en) 1998-05-29 2015-02-25 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
KR100659803B1 (ko) 1998-09-30 2006-12-19 와이어쓰 홀딩스 코포레이션 보조제로서 돌연변이체 콜레라 홀로톡신
EP1198245B1 (en) * 1998-09-30 2004-08-25 Walter Reed Army Institute of Research Use of purified invaplex from gram negative bacteria as a vaccine
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
CN1350585A (zh) 1999-01-15 2002-05-22 史密丝克莱恩比彻姆生物有限公司 脑膜炎奈瑟氏菌多肽basb052
EP1147194A1 (en) 1999-01-22 2001-10-24 SMITHKLINE BEECHAM BIOLOGICALS s.a. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
ATE413188T1 (de) 1999-02-05 2008-11-15 Merck & Co Inc Menschliche papillomavirus impfstoff- formulierungen
DE60015084T2 (de) 1999-02-26 2006-02-16 Chiron S.R.L. Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
CN100392082C (zh) 1999-04-30 2008-06-04 启龙股份公司 保守的奈瑟球菌抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP2270172B1 (en) * 1999-05-19 2016-01-13 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
RU2002117308A (ru) 1999-11-29 2004-03-10 Чирон Спа (It) 85 кДа АНТИГЕН NEISSERIA
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2292263A3 (en) 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
EP1261723B1 (en) * 2000-02-28 2008-02-27 Novartis Vaccines and Diagnostics S.r.l. Hybrid expression of neisserial proteins
AU8181201A (en) 2000-06-08 2001-12-17 Cistem Biotechnologies Gmbh Immunostimulatory oligodeoxynucleotides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1355673B1 (en) 2001-01-23 2012-05-30 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2441327A1 (en) 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
AU2002258734A1 (en) 2001-04-13 2002-10-28 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
AU2002252638A1 (en) 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
IL159210A0 (en) 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
MXPA03011135A (es) 2001-06-07 2004-09-08 Wyeth Corp Formas mutantes de holotoxina de colera como adyuvante.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP2005508630A (ja) * 2001-09-14 2005-04-07 インヴィトロジェン コーポレーション Ｄｎａポリメラーゼとその変異体
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
BR0308768A (pt) 2002-03-26 2005-02-15 Chiron Srl Sacarìdeos modificados possuindo estabilidade melhorada em água
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
EP1506007B1 (en) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
NZ562998A (en) 2002-10-11 2008-05-30 Novartis Vaccines & Diagnostic Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004065603A2 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
PT2172213E (pt) 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CN1867354A (zh) 2003-04-16 2006-11-22 惠氏控股有限公司 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物
ES2328697T5 (es) 2003-06-02 2017-07-25 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
EP1644036A2 (en) 2003-06-23 2006-04-12 Sanofi Pasteur Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
MXPA06007635A (es) 2003-12-30 2007-01-30 Wyeth Corp Formulaciones de proteinas hidrofobas en una composicion inmunogenica que tiene tolerabilidad mejorada.
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP1740217B1 (en) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006011060A2 (en) 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
EP2682126B1 (en) * 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
JP2008533016A (ja) 2005-03-07 2008-08-21 アイディー バイオメディカル コーポレイション オブ ケベック シー．オー．ビー． アズ グラクソスミスクライン バイオロジカルズ ノース アメリカ 薬学的リポソーム組成物
CN101282984B (zh) 2005-05-06 2013-05-08 诺华疫苗与诊断股份有限公司 A型脑膜炎疫苗的免疫原
UA95237C2 (uk) 2005-06-27 2011-07-25 Ґлаксосмітклайн Байолоджікалз С.А. Імуногенна композиція
EP1967204B1 (en) 2005-09-01 2013-10-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccination including serogroup c meningococcus
WO2007028408A1 (en) 2005-09-05 2007-03-15 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
JP2009520771A (ja) 2005-12-23 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム コンジュゲートワクチン
EP2357001B1 (en) 2006-03-22 2018-03-07 GlaxoSmithKline Biologicals S.A. Regimens for immunisation with meningococcal conjugates
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007144317A2 (en) 2006-06-12 2007-12-21 Glaxosmithlline Biologicals Sa Vaccine
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
WO2008001224A2 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
ES2788001T3 (es) 2006-07-27 2020-10-20 Wyeth Llc Procedimiento de fermentación de alimentación discontinua de alta densidad celular para producir proteínas recombinantes
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0811979A2 (pt) 2007-06-04 2014-10-21 Novartis Ag Formulação para vacinas de meningite
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009038889A1 (en) * 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
ATE553774T1 (de) 2007-10-19 2012-05-15 Novartis Ag Meningokokkenimpfstoffformulierungen
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
WO2009109550A1 (en) 2008-03-05 2009-09-11 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2009143168A2 (en) 2008-05-19 2009-11-26 Novartis Ag Vaccine assays
RU2477145C2 (ru) 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
CN102203276A (zh) 2008-08-27 2011-09-28 奥克兰儿童医院及研究中心 基于补体因子h对脑膜炎奈瑟球菌血清杀菌活性的鉴定
WO2010028096A2 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
WO2010077422A2 (en) 2008-10-29 2010-07-08 Wyeth Llc Formulations of single domain antigen binding molecules
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (ja) * 2008-12-15 2014-02-05 川上産業株式会社 梱包箱及び箱状芯材
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CN104548082A (zh) * 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
RU2555757C2 (ru) 2009-03-24 2015-07-10 Новартис Аг Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
CA2759400A1 (en) 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (ja) * 2009-10-22 2010-03-25 王　文燦 折畳める物置袋
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2519265B1 (en) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CN102869378A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
MX2012010609A (es) 2010-03-18 2012-10-03 Novartis Ag Vacunas adyuvadas para meningococos serogrupo b.
EP4036104B1 (en) 2010-03-30 2024-02-21 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
US9057716B2 (en) 2010-09-04 2015-06-16 Novartis Ag Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
MY166172A (en) 2010-09-10 2018-06-07 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
RU2013144207A (ru) 2011-03-02 2015-04-10 Новартис Аг Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
CA2960030C (en) 2012-03-09 2020-02-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
AU2014316722B2 (en) 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP7010961B2 (ja) 2017-01-31 2022-02-10 ファイザー・インク 髄膜炎菌組成物およびその方法

Also Published As

Publication number Publication date
ES2561430T3 (es) 2016-02-26
KR20040066793A (ko) 2004-07-27
DK2332961T3 (en) 2016-10-03
US9623101B2 (en) 2017-04-18
CN102836426B (zh) 2016-09-28
JP5404441B2 (ja) 2014-01-29
PT2371836T (pt) 2017-02-17
DK2343308T3 (en) 2015-03-30
EP2348035A2 (en) 2011-07-27
IL161052A0 (en) 2004-08-31
AU2009213040C1 (en) 2012-10-11
PT2341063E (pt) 2015-10-29
EP2348036A3 (en) 2011-08-03
JP2017025061A (ja) 2017-02-02
ES2603532T3 (es) 2017-02-28
KR20100121699A (ko) 2010-11-18
US8563007B1 (en) 2013-10-22
AU2018203627A1 (en) 2018-06-07
ES2568895T3 (es) 2016-05-05
US20130259889A1 (en) 2013-10-03
JP2015214545A (ja) 2015-12-03
LUC00041I2 (enExample) 2017-12-20
EP2371837A1 (en) 2011-10-05
WO2003063766A3 (en) 2004-01-08
HK1178429A1 (zh) 2013-09-13
US20120034261A1 (en) 2012-02-09
CN102755631B (zh) 2015-11-25
US20170173140A1 (en) 2017-06-22
KR101068318B1 (ko) 2011-09-28
KR101215664B1 (ko) 2012-12-26
US9107873B2 (en) 2015-08-18
DK2351767T3 (en) 2015-10-26
EP2371837B1 (en) 2016-09-21
KR20110117726A (ko) 2011-10-27
ES2603531T3 (es) 2017-02-28
KR20100028657A (ko) 2010-03-12
IL233545A (en) 2017-10-31
CN1578785B (zh) 2013-03-13
CA2463476A1 (en) 2003-08-07
JP2014012002A (ja) 2014-01-23
ES2549765T3 (es) 2015-11-02
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
PT3199539T (pt) 2020-04-01
EP2348035A3 (en) 2011-09-14
CA2939781A1 (en) 2003-08-07
CA2939781C (en) 2022-09-13
IL161052A (en) 2015-04-30
US20120308595A1 (en) 2012-12-06
EP2348036B1 (en) 2015-12-16
EP2341062A3 (en) 2011-09-14
EP2348034A3 (en) 2011-09-21
IL245956A0 (en) 2016-07-31
ES2593360T3 (es) 2016-12-07
FR17C1042I1 (enExample) 2017-12-22
PT2343308E (pt) 2015-03-25
CA2918207A1 (en) 2003-08-07
EP2341063B1 (en) 2015-08-26
EP2366707A1 (en) 2011-09-21
US20060257413A1 (en) 2006-11-16
CA2894296A1 (en) 2003-08-07
EP3199539B1 (en) 2020-03-11
EP2343308B1 (en) 2015-02-18
JP2016165275A (ja) 2016-09-15
ES2532639T3 (es) 2015-03-30
EP2351767A3 (en) 2011-09-14
CA2849427C (en) 2016-10-04
IL245955B (en) 2018-01-31
NL300899I2 (nl) 2018-04-06
BR0212999A (pt) 2006-05-23
DK2371838T3 (en) 2016-02-22
ES2625876T3 (es) 2017-07-20
US8563006B2 (en) 2013-10-22
EP2332961A3 (en) 2011-07-27
DK2348036T3 (en) 2016-02-22
DK3199539T3 (da) 2020-04-27
EP2371836B1 (en) 2016-12-14
EP3199539A1 (en) 2017-08-02
JP5923070B2 (ja) 2016-05-24
NL300897I2 (nl) 2018-04-06
EP2366707B1 (en) 2016-09-21
JP5997400B2 (ja) 2016-09-28
EP2343308A2 (en) 2011-07-13
HK1178800A1 (zh) 2013-09-19
US9168293B2 (en) 2015-10-27
EP2351767B1 (en) 2015-08-26
FR17C1042I2 (fr) 2018-12-07
PT2348036E (pt) 2016-03-09
PT2332961T (pt) 2016-09-28
EP2343308A3 (en) 2011-07-27
EP1442047A4 (en) 2005-06-01
CA2849427A1 (en) 2003-08-07
EP1442047B1 (en) 2016-03-16
EP2371838B1 (en) 2015-12-16
ES2549764T3 (es) 2015-11-02
EP2341062A2 (en) 2011-07-06
EP2348034A2 (en) 2011-07-27
EP2348035B1 (en) 2015-02-18
US20120301496A1 (en) 2012-11-29
JP5976880B2 (ja) 2016-08-24
BE2017C056I2 (enExample) 2022-02-01
NL300897I1 (nl) 2017-10-20
MX339524B (es) 2016-05-30
IL245956B (en) 2019-02-28
DK2341063T3 (en) 2015-10-26
ES2609039T3 (es) 2017-04-18
NL300899I1 (nl) 2017-10-20
DK2371836T3 (en) 2017-02-20
US20190151431A1 (en) 2019-05-23
PT2348035E (pt) 2015-03-25
BE2017C055I2 (enExample) 2022-02-01
ES2781213T3 (es) 2020-08-31
US20150216960A1 (en) 2015-08-06
NL300896I1 (nl) 2017-10-20
PT2371838E (pt) 2016-03-23
CN105617372A (zh) 2016-06-01
BE2017C057I2 (enExample) 2022-02-01
AU2009213040A1 (en) 2009-10-08
ES2615206T3 (es) 2017-06-05
LUC00041I1 (enExample) 2017-10-16
PT2341062T (pt) 2017-06-02
US20110076299A1 (en) 2011-03-31
CA2918207C (en) 2016-10-18
EP2348036A2 (en) 2011-07-27
EP2371836A1 (en) 2011-10-05
PT2351767E (pt) 2015-10-30
JP2010162023A (ja) 2010-07-29
AU2012202916C1 (en) 2017-06-08
AU2009213040B2 (en) 2012-03-01
LUC00040I1 (enExample) 2017-10-16
US10300122B2 (en) 2019-05-28
AU2012202916B2 (en) 2013-08-01
FR17C1043I1 (enExample) 2017-12-22
IL245955A0 (en) 2016-07-31
ES2562811T3 (es) 2016-03-08
EP2371838A1 (en) 2011-10-05
DK2348035T3 (en) 2015-04-20
NL300896I2 (nl) 2018-04-06
LUC00042I2 (enExample) 2017-12-20
CA2894296C (en) 2018-05-01
US11116829B2 (en) 2021-09-14
ES2532640T3 (es) 2015-03-30
US20120294880A1 (en) 2012-11-22
LUC00042I1 (enExample) 2017-10-16
EP2341063A2 (en) 2011-07-06
FR17C1044I1 (enExample) 2017-12-22
US8101194B2 (en) 2012-01-24
FR15C0056I1 (enExample) 2015-09-11
US9757444B2 (en) 2017-09-12
BRPI0212999B1 (pt) 2020-04-28
LUC00040I2 (enExample) 2017-12-20
EP1442047A2 (en) 2004-08-04
EP2348034B1 (en) 2016-11-02
AU2012202916A1 (en) 2012-06-07
JP2005515771A (ja) 2005-06-02
EP2341062B1 (en) 2017-03-29
FR15C0056I2 (fr) 2016-06-03
EP2332961A2 (en) 2011-06-15
LU92786I2 (fr) 2015-11-02
US20120201844A1 (en) 2012-08-09
US9132182B2 (en) 2015-09-15
FR17C1044I2 (fr) 2018-12-07
NL300755I2 (nl) 2025-11-25
EP2351767A2 (en) 2011-08-03
CN102755631A (zh) 2012-10-31
EP2341063A3 (en) 2011-09-14
CN1578785A (zh) 2005-02-09
KR101099916B1 (ko) 2011-12-28
IL233545A0 (en) 2014-08-31
FR17C1043I2 (fr) 2018-12-07
CN102836426A (zh) 2012-12-26
WO2003063766A2 (en) 2003-08-07
MXPA04003356A (es) 2004-11-29
MX349481B (es) 2017-07-31
CA2463476C (en) 2017-09-12
DK2341062T3 (en) 2017-05-08
EP2332961B1 (en) 2016-07-27

Similar Documents

Publication Publication Date Title
BRPI0212999B8 (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
BRPI0409459A (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
CA2438080A1 (en) Gonococcal proteins and nucleic acids
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BRPI0010612B8 (pt) vacinas
BRPI0515516A (pt) composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica
JP2003500040A5 (enExample)
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
HU229968B1 (hu) Sztreptokokkusz oltóanyag
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
NZ595063A (en) Polypeptides from neisseria meningitidis
RU2002103604A (ru) Антигенные менингококковые пептиды
BRPI0411875A (pt) método de imunização contra os sorogrupos a e c de neisseria meningitidis
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
WO2022160017A1 (en) Sars-cov-2 vaccine antigens
BR0313100A (pt) Composição imunogênica, composição imunogênica isolada, vacina, método de tratamento ou prevenção de doença bacteriana gram-negativa, uso da vacina, cepa bacteriana gram-negativa geneticamente manipulada, método para preparar a composição imunogênica, método para preparar a vacina, método de preparar uma imunoglobulina para uso na prevenção ou tratamento de infecção neisserial, preparação de imunoglobulina, preparação farmacêutica, e, uso da preparação farmacêutica
RU2000114245A (ru) Антигены нейссерий
ATE401341T1 (de) Vakzine enthaltend omp85 proteine von neisseria gonorrhoeae und neisseria meningitidis
Poolman et al. Nueva generación de vacunas antimeningococica basadas en vesículas de membrana externa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/2002, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/10/2022